Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject

A technology for metabolic syndrome and diabetes, which is applied in disease diagnosis, metabolic disease, biological testing, etc., and can solve problems such as undescribed correlations

Active Publication Date: 2013-09-18
SPHINGOTEC
View PDF23 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the same authors note that no clear association between circulating neurotensin and the stage of pancreatic, prostate, or medullary thyroid tumors has been described, which may be due to rapid hepatic clearance of neurotensin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject
  • A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject
  • A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0086] Antibody preparation

[0087] Peptides / Conjugates for Immunization

[0088] Peptides for immunization were synthesized (JPT Technologies, Berlin, Germany) with an additional N-terminal cysteine ​​residue to couple the peptide to bovine serum albumin (BSA). The peptide was covalently coupled to BSA by using Sulfo-SMCC (Perbio-science, Bonn, Germany). Coupling steps were performed according to Perbio's manual.

[0089] Labeled Antibody (LA) Peptides (P-NT 1-19):

[0090] H-CSDSEEEMKALEADFLTNMH-NH2

[0091] Solid Phase Antibody (SPA) Peptide (P-NT 44-62):

[0092] H-CNLNSPAEETGEVHEEELVA-NH2

[0093] Generate antibodies as follows:

[0094] BALB / c mice were immunized with 100 μg of peptide-BSA conjugate on days 0 and 14 (emulsified in 100 μl complete Freund’s adjuvant) and 50 μg on days 21 and 28 (in 100 μl in incomplete Freund's adjuvant). Animals received 50 μg of conjugate dissolved in 100 μl of saline by one intraperitoneal injection and one intravenous injectio...

Embodiment 2

[0101] Immunoassay for quantification of human proneurotensin

[0102] The technique used is based on acridinium ester labeled sandwich-coated tube luminescence immunoassay.

[0103] Labeled complex (tracer): 100 μg (100 μl) LA (1 mg / ml dissolved in PBS, pH 7.4) was mixed with 10 μl acridine NHS ester (1 mg / ml dissolved in acetonitrile, InVent GmbH, Germany) (EP 0353971 ) and incubate at room temperature for 20 minutes. Labeled LA was purified by gel filtration HPLC on Bio-Sil SEC 400-5 (Bio-Rad Laboratories, Inc., USA). Purified LA was diluted in (300 mmol / l potassium phosphate, 100 mmol / l NaCl, 10 mmol / l Na-EDTA, 5 g / l bovine serum albumin, pH 7.0). The final concentration was about 800.000 relative light units (RLU) of labeled complex (about 20 ng of labeled antibody) per 200 μl. Acridinium ester chemiluminescence was measured with AutoLumat LB 953 (Berthold Technologies GmbH & Co. KG).

[0104] Solid phase: Polystyrene tubes (Greiner Bio-One International AG, Austria) ...

Embodiment 3

[0113] group study

[0114] We measured P-NT in fasting plasma from 4362 participants (mean age 58±6 years, 59% female) who underwent the baseline examination of the Malmö Diet and Cancer Study in 1991-1994. crowd. We compared baseline P-NT (to log-transformed P- Hazard ratio per one standard deviation increase in NT) was associated with time to first event for each study endpoint, with a median follow-up of more than 12 years. Endpoints were retrieved from the Swedish National Hospital Discharge Register, the Swedish Myocardial Infarction Register, the Malmö Stroke Register, and the Swedish Cancer Register. Endpoints retrieved through these registries were validated and found to be accurate.

[0115] Table 1

[0116] Clinical characteristics of the total study population

[0117] descriptive statistics

[0118]

[0119] Table 2

[0120] gender

[0121]

[0122] table 3

[0123] Questionnaire + diary records: Antihypertensive treatment at baseline obtained f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Subject matter of the present invention is a method for predicting the risk of a subject for contracting diabetes mellitus and / or metabolic syndrome or for diagnosing metabolic syndrome in a subject wherein said subject is non-diabetic, comprising the following steps determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of pro-neurotensin or fragments thereof with the risk of said subject for contracting diabetes mellitus and / or metabolic syndrome, wherein an elevated level is predictive for an enhanced risk of getting diabetes mellitus and / or metabolic syndrome, or wherein an elevated level correlates to the diagnosis of metabolic syndrome in a subject wherein said subject is non-diabetic.

Description

technical field [0001] A subject of the present invention is a method for predicting the risk of diabetes and / or metabolic syndrome in a subject or for diagnosing metabolic syndrome in a subject, wherein said subject is not diabetic, said method comprising the following steps: [0002] Determining the level of proneurotensin or a fragment thereof of at least 5 amino acids in a body fluid obtained from said subject; and [0003] correlating said levels of proneurotensin or fragments thereof with said subject's risk of developing diabetes and / or metabolic syndrome, wherein elevated levels predict increased risk of developing diabetes and / or metabolic syndrome, or wherein Elevated levels correlate with a diagnosis of metabolic syndrome in a subject, wherein the subject does not have diabetes. [0004] The term "elevated level" means a level above a certain threshold level. Background technique [0005] Neurotensin is a 13 amino acid neuropeptide derived from the precursor of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/50
CPCG01N2800/042G01N33/6893A61P43/00A61P3/10G01N33/00G01N33/68G01N2333/4706
Inventor 安德里斯·贝格曼欧勒·米兰德
Owner SPHINGOTEC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com